TNFα-based isolated Hyperthermic Limb Perfusion (HILP) in the treatment of limb recurrent melanoma: Update 16 years after its first clinical application

Franco Di Filippo, F. Cavaliere, R. Garinei, M. Anzà, P. Di Angelo, A. Psaila, L. Piarulli, A. Callopoli, P. Bruno, S. Di Filippo, F. Priore

Research output: Contribution to journalArticle

Abstract

Hyperthermic Limb Perfusion (HILP) with Tumor Necrosis Factor alpha (TNFα) and interferon gamma (IFNγ) was pioneered by Lienard and Lejeune in 1988. TNFα was empirically employed at a dosage of 3-4 mg that is ten times the systemic maximum tolerated dose (MTD). Sixteen years after its first clinical application more than 300 patients have been treated and some clarifications can be made regarding three major questions: the real role of IFNγ, the TNFα dose and eligibility criteria for patient selection. A randomised phase II study has demonstrated that IFNγ does not increase significantly the efficacy but does increase side-effects. Experimental and clinical results seem to indicate that patients with bulky melanoma disease can really benefit from TNFα HILP carried out with only 1 mg.

Original languageEnglish
Pages (from-to)62-65
Number of pages4
JournalJournal of Chemotherapy
Volume16
Issue numberSUPPL. 5
Publication statusPublished - Nov 2004

Keywords

  • HILP
  • Melanoma
  • TNF

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'TNFα-based isolated Hyperthermic Limb Perfusion (HILP) in the treatment of limb recurrent melanoma: Update 16 years after its first clinical application'. Together they form a unique fingerprint.

  • Cite this

    Di Filippo, F., Cavaliere, F., Garinei, R., Anzà, M., Di Angelo, P., Psaila, A., Piarulli, L., Callopoli, A., Bruno, P., Di Filippo, S., & Priore, F. (2004). TNFα-based isolated Hyperthermic Limb Perfusion (HILP) in the treatment of limb recurrent melanoma: Update 16 years after its first clinical application. Journal of Chemotherapy, 16(SUPPL. 5), 62-65.